These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37612090)

  • 1. Lung Cancer Wherein Durvalumab Induced Both Anti-CRMP-5 Antibody-related Paraneoplastic Neurological Syndromes and Neurological Adverse Events.
    Seki T; Baba K; Hayashi T; Furuta R; Hirosawa H; Mitsui T; Maesaka H; Takasawa S; Miwa T; Tanaka K; Nakatsuji Y
    Intern Med; 2024 Apr; 63(7):1009-1014. PubMed ID: 37612090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer.
    Wang L; Lou H; Li B; Li J; Yang YM
    Invest New Drugs; 2022 Feb; 40(1):151-156. PubMed ID: 34287773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab-induced cerebellar ataxia in a patient with metastatic small cell lung cancer: A case report and literature review.
    Kapagan T; Aksu F; Yuzkan S; Bulut N; Erdem GU
    J Oncol Pharm Pract; 2024 Jan; 30(1):201-205. PubMed ID: 37321205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment.
    Iwanaga Y; Kawaguchi T; Yamasaki K; Sato T; Kubo N; Morimoto T; Isoshima Y; Sasahara Y; Orihashi T; Yatera K
    Thorac Cancer; 2023 Jul; 14(19):1899-1903. PubMed ID: 37253448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-cell Lung Carcinoma with Gastrointestinal Pseudo-obstruction as a Paraneoplastic Neurological Syndrome Elicited by an Immune Checkpoint Inhibitor.
    Saitou A; Shioya M; Nagahisa Y; Haseyama A; Niwa R; Tsuchimoto J; Chiba H
    Intern Med; 2024 Jul; 63(14):2059-2062. PubMed ID: 38044152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Limbic encephalitis following treatment with durvalumab for small-cell lung cancer.
    Moss TT; Stavem K; Aandahl A; Gløersen AS; Grønberg BH; Neumann K; Vedeler CA; Lundqvist C
    Front Immunol; 2023; 14():1278761. PubMed ID: 37908347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double trouble: para-neoplastic anti-PCA-2 and CRMP-5-mediated small fibre neuropathy followed by chorea associated with small cell lung cancer and evolving radiological features.
    Waheed W; Boyd J; Khan F; Mount SL; Borden NM; Tandan R
    BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27571910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CV2/CRMP5-antibody-related Paraneoplastic Neurologic Syndrome Associated with Gastrointestinal Stromal Tumor.
    Fukushima H; Shibuya T; Awatsu T; Kurosawa T; Haga K; Murakami T; Serizawa N; Mori A; Hojo M; Yao T; Hattori N; Nagahara A
    Intern Med; 2022 May; 61(10):1497-1501. PubMed ID: 34670904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paraneoplastic Sensory Polyneuropathy Related to Anti-PD-L1-including Anticancer Treatment in a Patient with Lung Cancer.
    Morimoto T; Orihashi T; Yamasaki K; Tahara M; Kato K; Yatera K
    Intern Med; 2021 May; 60(10):1577-1581. PubMed ID: 33328400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CV2/CRMP5 antibody-positive paraneoplastic neurological syndromes with chronic intestinal pseudo-obstruction in a small-cell lung cancer patient: a case report and literature review.
    Yan J; Chen Z; Liang Y; Yang H; Cao L; Zhou Y; Zhao Y; Zhang Y
    J Int Med Res; 2020 Dec; 48(12):300060520974466. PubMed ID: 33305627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CV2/CRMP5-antibody-related Paraneoplastic Optic Neuropathy Associated with Small-cell Lung Cancer.
    Nakajima M; Uchibori A; Ogawa Y; Miyazaki T; Ichikawa Y; Kaneko K; Takahashi T; Nakashima I; Shiraishi H; Motomura M; Chiba A
    Intern Med; 2018 Jun; 57(11):1645-1649. PubMed ID: 29321433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paraneoplastic Encephalitis and Enteric Neuropathy Associated With Anti-Hu Antibody in a Patient Following Immune-checkpoint Inhibitor Therapy.
    Kang K; Zheng K; Zhang Y
    J Immunother; 2020 Jun; 43(5):165-168. PubMed ID: 32195750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors.
    Duong SL; Prüss H
    Neurotherapeutics; 2022 Apr; 19(3):848-863. PubMed ID: 35043373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paraneoplastic Opsoclonus-myoclonus Syndrome with Anti-Hu and Anti-SOX-1 Antibodies after Immune-checkpoint Inhibitor Treatment Combined with Chemotherapy in a Patient with Small-cell Lung Cancer.
    Arai H; Utsu Y; Horio J; Furukawa S; Kikkawa Y
    Intern Med; 2022; 61(1):71-74. PubMed ID: 34980760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-SOX1 antibody-positive paraneoplastic neurological syndrome presenting with Lambert-Eaton myasthenic syndrome and small cell lung cancer: A case report.
    Li C; Wang X; Sun L; Deng H; Han Y; Zheng W
    Thorac Cancer; 2020 Feb; 11(2):465-469. PubMed ID: 31880403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encephalitis Induced by Durvalumab During Treatment of Metastatic Small-Cell Lung Cancer: Illustrative Case and Review of the Literature.
    Shechtman Y; Shalata W; Khoury R; Mahajna A; Weller B; Agbarya A
    J Immunother; 2021 Sep; 44(7):243-247. PubMed ID: 33734140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgG4-related pleural disease in a patient with pulmonary adenocarcinoma under durvalumab treatment: a case report.
    Terashima T; Iwami E; Shimada T; Kuroda A; Matsuzaki T; Nakajima T; Sasaki A; Eguchi K
    BMC Pulm Med; 2020 Apr; 20(1):104. PubMed ID: 32334571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes.
    Farina A; Villagrán-García M; Vogrig A; Zekeridou A; Muñiz-Castrillo S; Velasco R; Guidon AC; Joubert B; Honnorat J
    Lancet Neurol; 2024 Jan; 23(1):81-94. PubMed ID: 38101905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
    Fonseca E; Cabrera-Maqueda JM; Ruiz-García R; Naranjo L; Diaz-Pedroche C; Velasco R; Macias-Gómez A; Milisenda JC; Muñoz-Farjas E; Pascual-Goñi E; Gállego Perez-Larraya J; Saiz A; Dalmau J; Blanco Y; Graus F; Martinez-Hernandez E;
    Lancet Neurol; 2023 Dec; 22(12):1150-1159. PubMed ID: 37977714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes.
    Nassar AH; El Zarif T; Khalid AB; Rahme S; Zhong C; Kwak L; Salame M; Farhat EB; Freeman D; El-Am E; Ravishankar A; Ahmad B; Nana FA; Kaldas D; Naqash AR; Sharon E; LeBoeuf NR; Cortellini A; Malgeri A; Gupta S; Al-Hader A; Sparks JA; Linnoila J; Hamnvik OR; Mouhieddine TH; Marron T; Parikh K; McKay RR; Dilling T; Choueiri TK; Adib E; Najem E; Kim SY; Sonpavde G
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38448038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.